VolitionRx Files Patent Applications for Nucleosomics

VolitionRx Limited

announces that it has filed two new patent applications. The first patent application is an extension to the Nucleosomics® technology for the detection of histone modifications in nucleosomes; the second covers the use of Volition's Nucleosomics® technology in personalized medicine as a predictor of the efficacy of cancer treatment. "The use of Nucleosomics in the expanding field of personalized cancer medicine is a new early stage development for us but represents an exciting prospect with the potential for real patient benefit," said Jake Micallef, Chief Scientific Officer of Belgian Volition. VolitionRx already holds patent applications worldwide for a number of methods of detecting nucleosomes and nucleosome structures; both in-licensed and self-authored. "These two patents complement our existing Nucleosomics IP, providing us with greater intellectual property protection for our NuQ® products," said Cameron Reynolds, CEO of VolitionRx. "While we work towards applying for regulatory approval for our clinical products in both Europe and the US, we continue to carry out research and development in our Belgian laboratory, expanding our intellectual property base and our understanding of the possibilities – both in diagnostics